Fmr LLC lessened its stake in shares of BioScrip Inc (NASDAQ:BIOS) by 26.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,080,432 shares of the company’s stock after selling 1,449,978 shares during the period. Fmr LLC owned about 3.19% of BioScrip worth $14,567,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Maven Securities LTD acquired a new stake in shares of BioScrip during the 4th quarter valued at $45,000. Caxton Associates LP acquired a new stake in shares of BioScrip during the 4th quarter valued at $52,000. Virtu Financial LLC lifted its position in shares of BioScrip by 60.6% during the 4th quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after acquiring an additional 6,868 shares during the last quarter. Menta Capital LLC acquired a new stake in shares of BioScrip during the 4th quarter valued at $124,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in shares of BioScrip by 383.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $161,000 after acquiring an additional 35,700 shares during the last quarter. Institutional investors own 82.58% of the company’s stock.
A number of equities research analysts have recently commented on the company. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a report on Monday, November 26th. Zacks Investment Research lowered BioScrip from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Stephens lowered BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 target price for the company. in a report on Monday, March 18th. Finally, Canaccord Genuity reduced their target price on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a report on Monday, March 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $4.70.
BioScrip (NASDAQ:BIOS) last released its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.11). The firm had revenue of $183.57 million during the quarter, compared to the consensus estimate of $188.39 million. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.03) EPS. Equities analysts predict that BioScrip Inc will post -0.22 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Fmr LLC Sells 1,449,978 Shares of BioScrip Inc (BIOS)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4244965/fmr-llc-sells-1449978-shares-of-bioscrip-inc-bios.html.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Further Reading: How do taxes affect a CDs total return?
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip Inc (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.